Clinical Trial

Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial

Study acronym: HART
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective single-center single-arm Phase II trial of HART for patients with metastatic cancer. The primary objective is to assess the incidence of acute GI toxicity following HART. PRO-CTCAE GI scores observed in the study patients will be compared to historical rates. Secondary outcomes include measuring changes in health-related quality of life, esophageal quality of life, toxicity, dosimetric outcomes, and pain.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-10.
Status change: Not Yet Recruiting → Recruiting 2026-02-02
Trial Details
NCT Number NCT06778408
Lead Sponsor University of Vermont Medical Center
Conditions Palliative Radiotherapy, Metastatic Cancer (Different Solid Tumour Types)
Enrollment 103 participants
Start Date 2025-04-28
Primary Completion 2028-02 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-02-05